Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Completed · Phase 3 · Has a placebo group

Conditions studied: Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas

In brief

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Key facts

Study ID
NCT02184195
Run by
AstraZeneca
People needed
154
Starts
2014-12-16
Expected to finish
2023-01-27
Last updated by the study team
2023-09-13

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.